Form 4: Cardiff Oncology's Chief Scientific Officer, Tod Smeal, Reports Stock Option Grant

Tod Smeal, Chief Scientific Officer of Cardiff Oncology, reports the acquisition of stock options.

Summary

• On March 7, 2024, Tod Smeal, the Chief Scientific Officer of Cardiff Oncology, Inc., reported a transaction involving derivative securities.
• Smeal acquired 205,008 stock options with an exercise price of $3.51.
• These options vest 25% on March 7, 2025, and the remaining shares vest in 36 equal monthly installments thereafter, contingent upon continued service.
• Following the reported transaction, Smeal directly owns 647,184 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key employees and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies.
• The size of the grant and the vesting schedule are typical for a Chief Scientific Officer at a company like Cardiff Oncology.

Stakeholder Impact

• The stock option grant aligns the Chief Scientific Officer's interests with those of the shareholders, potentially driving long-term value creation.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates